https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/2242/phase-2-study-darolutamide/?qd=30331522
A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Na ve...
New life-saving treatments for Salivary Gland Cancer|Head and Neck cancers in clinical trial on A Phase 2 Study of Darolutamide in Combination with Leuprolide...
https://ec2-3-220-198-172.compute-1.amazonaws.com/jco-24-01798-prostate-cancer/
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic...
Feb 10, 2025 - Another study showing the benefits of adding AR blocker to ADT. Improved PFs and suggestive improvement in OS, also less fatigue.
darolutamidecombinationandrogendeprivationtherapy
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-metastatic-castration-sensitive-prostate-cancer
FDA approves darolutamide for metastatic castration-sensitive prostate cancer | FDA
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic...
fda approvesdarolutamidemetastaticcastrationsensitive
https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/2242/phase-2-study-darolutamide/?section=elg
A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Na ve...
New life-saving treatments for Salivary Gland Cancer|Head and Neck cancers in clinical trial on A Phase 2 Study of Darolutamide in Combination with Leuprolide...
https://www.cancer.gov/news-events/cancer-currents-blog/2022/darolutamide-survival-metastatic-prostate-cancer
Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.
metastatic prostate cancerdarolutamideextendssurvivalnci